Inflammation in Ischemic Stroke: Biomarkers and Treatment Pa
2026-05-07
This review systematically synthesizes current understanding of inflammation's role in ischemic stroke, highlighting both the molecular mechanisms and the clinical significance of inflammatory biomarkers. The paper guides researchers and clinicians through recent advances and integrated therapeutic strategies, providing a comprehensive reference for translational and experimental studies.
Flavone 2'-Glucosides and Baicalin Methyl Ester from S. baic
2026-05-06
This study isolated and structurally characterized two novel flavone 2'-O-glucosides and seven known phenolics, including baicalin methyl ester, from Scutellaria baicalensis roots. The findings deepen understanding of the chemical diversity in this medicinal herb and clarify the molecular groundwork for ongoing research on anti-inflammatory agents targeting intestinal barrier function.
Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat
2026-05-06
This study reveals that certain kinase inhibitors not only block p38α MAP kinase activity but also promote its dephosphorylation by stabilizing activation loop conformations accessible to phosphatases. These dual-action inhibitors provide a new avenue for enhancing specificity and potency in kinase-targeted inflammatory disease research.
G007-LK Tankyrase 1/2 Inhibitor: Workflow, Use Cases & Tips
2026-05-05
G007-LK, a potent tankyrase 1/2 inhibitor from APExBIO, empowers researchers to dissect Wnt/β-catenin and Hippo signaling with nanomolar precision. This article details protocol enhancements, advanced applications in APC mutation colorectal cancer and HCC, and practical troubleshooting strategies for robust, reproducible results.
Deuterium-Labeled Degarelix Acetate: Synthesis for Research
2026-05-05
This study reports an efficient 13-step synthesis of deuterium-labeled degarelix acetate, a third-generation GnRH receptor antagonist used in prostate cancer research. The labeled compound enables precise internal standards for pharmacokinetic and metabolism studies, supporting advanced hormone pathway investigations.
IWR-1-endo: Translational Leverage for Wnt Pathway Inhibitio
2026-05-04
This thought-leadership article delivers a mechanistic and strategic roadmap for translational researchers leveraging IWR-1-endo as a Wnt signaling inhibitor. It interweaves evidence-backed protocol guidance, competitive context, and actionable insights for colorectal cancer and regenerative biology applications, while contextualizing findings from recent cardiomyopathy research to illustrate the broader impact of pathway targeting. The article advances the discussion beyond standard product pages by integrating mechanistic depth, comparative analysis, and translational foresight, with clear evidence labeling and workflow recommendations.
miR-184 Activation by SREBF2 Counters Granulosa Cell Apoptos
2026-05-04
This study identifies miR-184 as a key ovary-elevated microRNA, transcriptionally activated by SREBF2, that mitigates apoptosis in ovarian granulosa cells by inducing SMAD3 expression. The findings clarify the epigenetic regulation of follicular atresia, suggesting new molecular targets to improve ovarian health and female fertility.
Toremifene in Breast Cancer: 20 Years of Clinical Data Revie
2026-05-03
This review analyzes two decades of clinical research on toremifene, a selective estrogen receptor modulator (SERM), for hormone-sensitive breast cancer. The article discusses the comparative efficacy, safety, and mechanistic rationale of SERMs versus aromatase inhibitors, highlighting the implications for personalized endocrine therapy in breast cancer management.
Anti Reverse Cap Analog (ARCA): Molecular Precision for Maxi
2026-05-02
Explore how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, enables molecularly precise, orientation-specific mRNA capping to optimize synthetic mRNA translation efficiency. This article uniquely bridges molecular mechanism, assay design, and translational research applications.
FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone): A
2026-05-02
FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) unlocks precision control over mitochondrial uncoupling, enabling robust investigation of oxidative phosphorylation, HIF pathway inhibition, and immunometabolic reprogramming. This article provides actionable protocols, troubleshooting strategies, and direct insights from the latest research to maximize experimental success with APExBIO’s FCCP.
AP20187: Precision Chemical Inducer of Dimerization in Fusio
2026-05-01
AP20187 enables programmable control of protein interactions, unlocking advanced conditional gene therapy and regulated cell therapy strategies. This article details experimental workflows, troubleshooting, and how insights from 14-3-3 signaling research translate into practical use of AP20187 as a chemical inducer of dimerization.
Benzyl Quinolone Carboxylic Acid: Precision Tool for M1 Rece
2026-04-30
Benzyl Quinolone Carboxylic Acid (BQCA) uniquely enables selective M1 muscarinic acetylcholine receptor potentiation with proven advantages for cognitive and Alzheimer’s disease research. This guide details advanced experimental workflows, data-driven troubleshooting, and the latest mechanistic insights to maximize reproducibility and interpretability in neuronal signaling studies.
LC–MS/MS Unveils GS-441524 Prodrug Conversion Pathways In Vi
2026-04-30
This study introduces a novel GS-441524 prodrug (NGP-1) with improved bioavailability, leveraging advanced LC–MS/MS techniques to clarify its conversion to the active antiviral nucleoside across biological compartments. The findings provide a robust analytical framework for evaluating prodrug pharmacokinetics and inform future anti-SARS-CoV-2 nucleoside analog development.
Tetraethylammonium Chloride: Optimizing K+ Channel Blockade
2026-04-29
Tetraethylammonium chloride (TEAC) is the go-to potassium channel blocker for advanced ion conduction and vascular research. This article delivers actionable guidance on experimental setup, troubleshooting, and protocol optimization, leveraging APExBIO’s rigorously validated TEAC for reproducible and high-impact results.
Gepotidacin for Gonorrhea: Phase 2 Efficacy, Resistance, and
2026-04-29
This article reviews the phase 2 trial evaluating gepotidacin, a novel bacterial type II topoisomerase inhibitor, for the treatment of uncomplicated urogenital gonorrhea. The study demonstrates high efficacy, addresses antibiotic resistance challenges, and provides a methodological foundation relevant for researchers studying bacterial protein synthesis inhibitors and antibacterial agents.
466 records 20/32 page Previous Next First page 上5页 1617181920 下5页 Last page